Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2013298.pdf
Reference23 articles.
1. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587–595.
2. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti–cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (25): 6043–6053.
3. Batty AJ, Fisher D, Winn B, Wang Q, Tolley K, Rowen D (2011) Estimating quality of life in advanced melanoma; a comparison of standard gamble, SF-36 mapped, and EORTC QLQ-C30 mapped utilities. Value Health 14: A461–A462.
4. Beusterien KM, Szabo SM, Kotapati S, Mukherjee J, Hoos A, Hersey P, Middleton MR, Levy AR (2009) Societal preference values for advanced melanoma health states in the United Kingdom and Australia. Br J Cancer 101: 387–389.
5. Cole BF, Gelber RD, Anderson KM International Breast Cancer Study Group (1994) Parametric approaches to quality-adjusted survival analysis. Biometrics 50: 621–631.
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combination Therapy with Immune Checkpoint Inhibitors and Histone Deacetylase Inhibitors or Alkylating Agents;Cancer Management and Research;2024-07
2. Quality-Adjusted Survival in Patients with Recurrence of Breast Cancer Diagnosed by Asymptomatic or Symptomatic Opportunities;The Kurume Medical Journal;2022-12-31
3. Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature;Life;2022-08-24
4. Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms;Anti-Cancer Agents in Medicinal Chemistry;2020-09-07
5. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck;PharmacoEconomics;2019-04-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3